Anticancer monoclonal antibody - Boehringer Ingelheim/XencorAlternative Names: XmAb® high ADCC monoclonal antibody; XmAb™ Fc-based monoclonal antibody
Latest Information Update: 14 Apr 2016
At a glance
- Originator Boehringer Ingelheim; Xencor
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 01 Apr 2011 Phase-I clinical trials in Cancer in USA (Parenteral)